PRT062607 (Hydrochloride)

PRT062607 (Hydrochloride)

• CAS Number: 1370261-97-4
• UNSPSC Description: PRT062607 (P505-15) Hydrochloride is an orally available Syk inhibitor (IC50: 1 nM) that inhibits inflammation and induction Apoptosis. PRT062607 Hydrochloride exerts potent antitumor activity in tumor xenograft mouse models[1][2].
• Target Antigen: Apoptosis; FAK; Mixed Lineage Kinase; PAK; Pyk2; Src; Syk
• Type: Reference compound
• Related Pathways: Apoptosis;Cell Cycle/DNA Damage;Cytoskeleton;MAPK/ERK Pathway;Protein Tyrosine Kinase/RTK
• Applications: Cancer-Kinase/protease
• Field of Research: cancer
• Assay Protocol: https://www.medchemexpress.com/PRT062607-Hydrochloride.html
• Solubility: 10 mM in DMSO|DMSO : ≥ 33 mg/mL|H2O : ≥ 50 mg/mL
• Smiles: NC(C1=CN=C(N[C@H]2[C@@H](N)CCCC2)N=C1NC3=CC=CC(N4N=CC=N4)=C3)=O.[H]Cl
• Molecular Weight: 429.91
• References & Citations: [1]Spurgeon SE, et al. The selective SYK inhibitor P505-15 (PRT062607) inhibits B cell signaling and function in vitro and in vivo and augments the activity of fludarabine in chronic lymphocytic leukemia. J Pharmacol Exp Ther. 2013 Feb;344(2):378-87.|[2]Coffey G, et al. Specific inhibition of spleen tyrosine kinase suppresses leukocyte immune function and inflammation in animal models of rheumatoid arthritis. J Pharmacol Exp Ther. 2012 Feb;340(2):350-9.Harvard Medical School LINCS LIBRARY|Int J Ophthalmol. 2022 Jul 18;15(7):1044-1052.|Proc Natl Acad Sci U S A. 2022 Oct 25;119(43):e2207280119.
• Shipping Conditions: Room Temperature
• Clinical Information: Phase 2